M Pharmaceutical Inc. Announces Successful Findings from Second of Three Pilot Studies Validating Its Proprietary Reformulation of Orlistat, C-103 Eliminates 98% of Orlistat’s Gastrointestinal Adverse Effects - iCrowdNewswire

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

North America ( XML Feed )

Aug 29, 2016 3:01 AM ET

M Pharmaceutical Inc. Announces Successful Findings from Second of Three Pilot Studies Validating Its Proprietary Reformulation of Orlistat, C-103 Eliminates 98% of Orlistat’s Gastrointestinal Adverse Effects

Disclosure NewswireTM

iCrowdNewswire - Aug 29, 2016


Vancouver, BC – M Pharmaceutical Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the “Company” or “M Pharmaceutical Inc.”), today announced findings  from the second of three proprietary pilot studies, previously conducted, as it relates to the recently acquired Chelatexx technology, referred to as the Company’s C-103 project.  In this study, which was conducted in the USA, C-103 was over 98% effective in eliminating the GI adverse events associated with orlistat. This finding is consistent with the first of the three pilot study findings announced on August 11th, 2016.


M Pharmaceutical Inc. has conducted its review of the first two of three pilot studies related to company’s recently acquired patented Chelatexx technology. The results of the first two studies provide strong validation for the development of the C-103 reformulation of orlistat.


C-103 is a novel formulation of orlistat, patented until 2030 in the United States. Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Orlistat is the best-selling weight loss medication of all time with peak sales of over $900 million in 2007, but use is limited by socially unacceptable bowel-related side effects (fecal incontinence, oily spotting, and flatus with discharge). C-103 is a patented, proprietary combination of orlistat, simethicone and activated charcoal, which is designed to maintain the efficacy of orlistat while minimizing its bowel-related side effects. The drugs are not systemically absorbed, and all are approved by the FDA for OTC usage and have strong safety profiles.


This second pilot study was titled, “Open label, single center pilot proof of concept study to assess a combination of orlistat, simethicome and activated charcoal in ameliorating the gastrointestinal adverse effects compared to orlistat taken alone as a single medication.” The primary study objective was to demonstrate the effectiveness of a patented, proprietary combination of orlistat, simethicome and activated charcoal to ameliorate the gastrointestinal adverse effects compared to orlistat API (active pharmaceutical ingredient) taken alone. Participants were not asked to change their diets for the study.


Highlights from the Study include:


  • The study was conducted at a single center in the United States over two weeks with twenty subjects, 10 females and 10 males;


  • The test agent – C103, was taken two times daily with two meals over the study duration. All dosage components of the test agent were used in accordance with their approved labeling and indications for use;


  • In terms of overall efficacy, C-103 was over 98% effective in eliminating (preventing) the gastrointestinal adverse events compared to orlistat alone. The rate of adverse events was 1.4% (4 adverse events/280 meals).


“FDA research has documented that over 90% of orlistat users have experienced adverse events termed underwear issues.  According to FDA data, approximately 90% of orlistat users discontinue the product within a month due to those underwear issues,” said Mr. Gary Thompson, President of M Pharmaceutical USA, Inc.


“Working with the knowledge that the Chelatexx technology (C-103) has the potential to significantly reduce the adverse events commonly experienced by consumers of orlistat, our objective is to formulate these technologies, orlistat & Chelatexx, into one Sequential Release Duel Compartment Capsule that maintains the efficacy of orlistat, but without the messy adverse events,” added Mr. Thompson.


“M Pharmaceutical Inc. believes the C-103 formulation can benefit millions of people who are struggling to maintain a healthy weight and it can do so over the long term without the high incidence of adverse events which result in people stopping treatment with orlistat alone after a short period of time,”  added M Pharmaceutical Inc. President and CEO, Mr. Brian Keane.


About M Pharmaceutical Inc.


Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to its recent acquisition of C-103, a reformulation of Orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. 


M Pharmaceutical Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”


For more information contact:


Investor Relations

Phone: +1 604 428 0511          

[email protected]



Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company’s biomedical & drug technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.


Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.  


Contact Information:

Investor Relations
+1 604 428 0511
[email protected]

View Related News >